Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein

SARS-CoV-2 enters host cells after binding through its spike glycoprotein to the angiotensin-converting enzyme 2 (ACE2) receptor. Soluble ACE2 ectodomains bind and neutralize the virus, yet their short in vivo half-live limits their therapeutic use. This limitation can be overcome by fusing the frag...

Descripción completa

Detalles Bibliográficos
Autores principales: Svilenov, Hristo L., Sacherl, Julia, Reiter, Alwin, Wolff, Lisa S., Cheng, Cho-Chin, Stern, Marcel, Grass, Vincent, Feuerherd, Martin, Wachs, Frank-Peter, Simonavicius, Nicole, Pippig, Susanne, Wolschin, Florian, Keppler, Oliver T., Buchner, Johannes, Brockmeyer, Carsten, Protzer, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579703/
https://www.ncbi.nlm.nih.gov/pubmed/34774603
http://dx.doi.org/10.1016/j.antiviral.2021.105197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579703/
https://www.ncbi.nlm.nih.gov/pubmed/34774603
http://dx.doi.org/10.1016/j.antiviral.2021.105197

Ejemplares similares